Passage Bio Inc (PASG)
$0.77
+0.04
(+6.06%)▲
Performance
- $0.69$0.79$0.77
10.39%
Downside
Day's Volatility :12.55%
Upside
2.41%
- $0.58$1.79$0.77
25.31%
Downside
52 Weeks Volatility :67.87%
Upside
56.98%
Returns
| Period | Passage Bio Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -35.41% | 4.7% | 0.0% |
6 Months | -49.71% | 5.1% | 0.0% |
1 Year | -7.36% | 16.6% | 0.0% |
3 Years | -93.7% | 15.6% | -20.6% |
Highlights
Market Capitalization | 43.5M |
Book Value | $1.47 |
Earnings Per Share (EPS) | -1.47 |
Wall Street Target Price | 6.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -34.48% |
Return On Equity TTM | -63.55% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -84.7M |
Diluted Eps TTM | -1.47 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.88 |
EPS Estimate Next Year | -0.5 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.3 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 776.62%
Technicals Summary
Sell
Neutral
Buy
Passage Bio Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Passage Bio Inc | -11.11% | -49.71% | -7.36% | -93.7% | -96.83% |
 Regeneron Pharmaceuticals, Inc. | 0.93% | 17.32% | 35.75% | 73.95% | 298.81% |
 Novo Nordisk A/s | 0.96% | -0.08% | 31.44% | 163.47% | 428.79% |
 Alnylam Pharmaceuticals, Inc. | -8.66% | 65.51% | 21.14% | 30.19% | 192.84% |
 Vertex Pharmaceuticals Incorporated | 0.75% | 12.92% | 34.78% | 148.18% | 173.67% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Passage Bio Inc | NA | NA | NA | -0.88 | -0.64 | -0.34 | NA | 1.47 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Passage Bio Inc | Buy | $43.5M | -96.83% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 298.81% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 428.79% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 192.84% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 173.67% | 32.84 | -4.74% |
Insights on Passage Bio Inc
Vs VRTX
In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 44.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 148.2% return, outperforming this stock by 241.9%
Institutional Holdings
Orbimed Advisors, LLC
16.39%Vestal Point Capital LP
9.80%Versant Venture Management LLC
6.52%New Leaf Venture Partners, L.L.C.
4.04%Vanguard Group Inc
3.35%TANG CAPITAL MANAGEMENT LLC
2.43%
Company Information
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
Organization | Passage Bio Inc |
Employees | 58 |
CEO | Dr. William Chou M.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$0.77
+6.06%
Keyarch Acquisition Corp
$0.77
+6.06%
Connexa Sports Technologies Inc
$0.77
+6.06%
Us Value Etf
$0.77
+6.06%
First Wave Biopharma Inc
$0.77
+6.06%
Global X Msci Next Emerging
$0.77
+6.06%
Fat Projects Acquisition Corp
$0.77
+6.06%
Capital Link Global Fintech
$0.77
+6.06%
Applied Uv Inc
$0.77
+6.06%